Alimera intends to supply that details when it becomes available. Related StoriesTARSA Therapeutics' TBRIA NDA accepted by FDA for reviewMylan announces U.S. Start of generic Fusilev for InjectionMylan announces U.S. Start of generic AXERT tablets In the resubmission, Alimera taken care of immediately questions elevated in the FDA's October 2013 complete response letter and provided a safety update, which included commercial encounter with ILUVIEN in European countries. ‘We are pleased to resubmit ILUVIEN for acceptance in the usa,’ stated Dan Myers, Alimera's president and ceo. ‘We look forward to an acknowledgment from the FDA that the response is certainly complete and a PDUFA time has been confirmed.’.. Alimera Sciences resubmits New Medication Application for ILUVIEN Alimera Sciences, Inc.S.Submissions will be recognized until February 1, 2011. To find out more and ALFA points of contact, please visit.
Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension Actelion Pharmaceuticals US, Inc. Announced the commercial availability of Epoprostenol for Injection today, a better formulation of epoprostenol that’s stable at room temperature, for the treatment of main pulmonary hypertension and pulmonary hypertension connected with scleroderma spectral range of disease in NYHA Class III and Class IV patients. Simultaneously, the company has launched the chance registry, a multicenter, observational, U.S.-centered registry that may provide additional medical experience on patients being treated with Epoprostenol for Injection.